The problem is the human existing in a modern environment that is hostile to it. GLP-1s enable the human to more effectively operate in said environment. It patches malfunctioning reward centers (addiction and food compulsion), it reduces overall inflammation, it provide cardiovascular protective properties.
As kubectl_h mentions [1], the future is better understanding and fine tuning the mechanisms responsible. I think gene therapy is the end goal (permanent fix vs chronic maintenance with GLP-1s), but others have indicated in previous threads that might not be possible. We need more information and research. This is only the beginning of the "Aha!" moment (The most exciting phrase to hear in science, the one that heralds new discoveries, is not “Eureka” but “That's funny...” —Isaac Asimov).
You're free to your opinion (legit, no snark intended), the market will deliver to the demand. The cost benefit ratio is obvious, even accounting for potential side effects at scale.
As kubectl_h mentions [1], the future is better understanding and fine tuning the mechanisms responsible. I think gene therapy is the end goal (permanent fix vs chronic maintenance with GLP-1s), but others have indicated in previous threads that might not be possible. We need more information and research. This is only the beginning of the "Aha!" moment (The most exciting phrase to hear in science, the one that heralds new discoveries, is not “Eureka” but “That's funny...” —Isaac Asimov).
[1] https://news.ycombinator.com/item?id=41989101